title: Discrimination between human T-cell lymphotropic virus type I and II (HTLV-I and HTLV-II) infections by using synthetic peptides representing an immunodominant region of the core protein (p19) of HTLV-I and HTLV-II.
abstract: We describe enzyme immunoassays that use synthetic oligopeptides to discriminate serologically between human T-cell lymphotropic virus type I and II (HTLV-I and HTLV-II) infections. The peptides represented 20-amino acid segments between residues 111 and 130 (MA1) and residues 116 and 135 (MA2) of the p19 gag proteins of HTLV-I and HTLV-II, respectively. The assays were sensitive since 69 of 74 HTLV-positive sera were reactive to at least one of the two matrix (MA) peptides (sensitivity, 93.2%). By using the ratio of the optical density of MA1 to the optical density of MA2, which represents for every serum sample the ratio between the absorbance value obtained in the MA1 assay and the absorbance value obtained in the MA2 assay, 59 of the 69 reactive serum samples were clearly and easily typed as positive for either antibody to HTLV-I or antibody to HTLV-II. Eight of the 10 remaining reactive serum samples were analyzed further by an inhibition procedure, and their type specificities were then clearly identifiable. Therefore, the results indicate that all MA-reactive sera were serologically distinguished by our peptide assays.
authors.affiliation: Laboratoire de Bactériologie-Virologie, Centre Hospitalier Universitaire Dupuytren, Limoges, France.
authors.forename: J
authors.initials: J
authors.lastname: Bonis
authors.forename: A
authors.initials: A
authors.lastname: Baillou
authors.forename: F
authors.initials: F
authors.lastname: Barin
authors.forename: M
authors.initials: M
authors.lastname: Verdier
authors.forename: B
authors.initials: B
authors.lastname: Janvier
authors.forename: F
authors.initials: F
authors.lastname: Denis
mesh_terms: D000595:Amino Acid Sequence; D005069:Evaluation Studies as Topic; D015683:Gene Products, gag / Q000235:genetics* / Q000276:immunology; D015481:HTLV-I Antibodies / Q000097:blood; D015490:HTLV-I Infections / Q000175:diagnosis* / Q000276:immunology; D015482:HTLV-II Antibodies / Q000097:blood; D015491:HTLV-II Infections / Q000175:diagnosis* / Q000276:immunology; D015368:Human T-lymphotropic virus 1 / Q000235:genetics / Q000276:immunology; D015367:Human T-lymphotropic virus 2 / Q000235:genetics / Q000276:immunology; D006801:Humans; D007124:Immunoenzyme Techniques / Q000706:statistics & numerical data; D008969:Molecular Sequence Data; D010455:Peptides / Q000138:chemical synthesis / Q000737:chemistry / Q000276:immunology; D015682:Retroviridae Proteins, Oncogenic / Q000235:genetics* / Q000276:immunology; D012680:Sensitivity and Specificity; D054301:gag Gene Products, Human Immunodeficiency Virus
chemical_list: D015683:Gene Products, gag; D015481:HTLV-I Antibodies; D015482:HTLV-II Antibodies; D010455:Peptides; D015682:Retroviridae Proteins, Oncogenic; D054301:gag Gene Products, Human Immunodeficiency Virus; C060955:p19 protein, Human T-lymphotropic virus 1